3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
6
Neoplasms
5
Neoplasm Metastasis
3
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Leukemia
2
Kidney Neoplasms
2
Carcinoma, Renal Cell
2
Vomiting
1
Stomatitis
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Alveolar Soft Part
1
Renal Insufficiency
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Paraproteinemias
1
Oncology Patients Receiving Chemotherapy
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Neoplasm, Residual
1
Nausea
1
NSCLC
1
Mucositis
1
Mastocytosis, Cutaneous
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Interventions
Cyclophosphamide
30
fludarabine phosphate
19
Peripheral Blood Stem Cell Transplantation
18
Tacrolimus
17
Mycophenolic Acid
16
Methotrexate
16
Whole-Body Irradiation
14
Etoposide
13
Vincristine
12
Doxorubicin
12
Dexamethasone
11
Busulfan
11
Cytarabine
10
Antilymphocyte Serum
10
venetoclax
9
Prednisone
9
nelarabine
8
Rituximab
8
Filgrastim
8
Cyclosporine
8
Calcium Dobesilate
8
merphos
7
Melphalan
7
Radiotherapy
6
prednylidene
5
deltacortene
5
Methylprednisolone
5
Azacitidine
5
Sirolimus
4
Granulocyte Colony-Stimulating Factor
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
×
Diphenhydramine
×
Clear all
NCT02999633
2022-03-21
ISLAY
Sanofi
Phase 2
Terminated
14 enrolled
7 charts